##  [Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis](/us-en/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-secukinumab-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis-0 "Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis") 

  Jan 15, 2016